Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction-Reference-Cited by-同舟云学术

Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction

Published:2002-06 Issue:6 Volume:97 Page:1408-1414
ISSN:0002-9270
Container-title:The American Journal of Gastroenterology
language:en
Short-container-title:Am J Gastroenterology

Author:

Kugathasan Subra,Levy Michael B.,Saeian Kia,Vasilopoulos Sotirios,Kim Joseph P.,Prajapati Devang,Emmons Jeanne,Martinez Alfonso,Kelly Kevin J.,Binion David G.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Reference15 articles.

1. A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

2. Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease

3. Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease

4. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience

5. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk factors for drug hypersensitivity reactions in children;Italian Journal of Pediatrics;2024-07-15

2. Delayed Ustekinumab Responders in Ulcerative Colitis Have Greater Inflammatory Burden but Similar Outcomes as Early Responders;Clinical Gastroenterology and Hepatology;2023-12

3. Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY Study;American Journal of Gastroenterology;2022-09-01

4. Efficacy and tolerability of infliximab retreatment in patients with inflammatory bowel disease: a systematic review and meta-analysis;Therapeutic Advances in Chronic Disease;2021-01

5. A possible case of serum sickness after ocrelizumab infusion;Multiple Sclerosis Journal;2020-05-19